Table of Contents
Overview
New York, NY – Dec 23, 2025 – The Global AI in Genomics Market size is expected to be worth around USD 35267.3 Million by 2033 from USD 733.4 Million in 2023, growing at a CAGR of 47.3% during the forecast period from 2024 to 2033.
Artificial Intelligence (AI) is increasingly being positioned as a foundational technology in genomics, enabling faster, more accurate, and scalable analysis of complex biological data. The integration of AI with genomics is transforming how genetic information is interpreted, accelerating discoveries across healthcare, biotechnology, and life sciences.
Genomic research generates vast volumes of data from DNA sequencing, gene expression profiling, and variant analysis. Traditional analytical methods are often limited in handling this scale and complexity. AI-based models, particularly machine learning and deep learning algorithms, are being applied to identify patterns, predict gene functions, and detect disease-associated variants with higher precision. As a result, the efficiency of genomic workflows is being significantly improved.
The basic formation of AI in genomics relies on three core components: high-quality genomic datasets, advanced computational infrastructure, and robust algorithm development. Structured datasets are used to train AI models, while cloud computing and high-performance processors support large-scale data processing. Algorithm optimization ensures reliable interpretation of genomic signals and biological relevance.
AI-driven genomics is being widely adopted in areas such as precision medicine, drug discovery, oncology research, and rare disease diagnostics. Personalized treatment strategies are being developed by correlating genetic profiles with clinical outcomes. In parallel, pharmaceutical research is benefiting from faster target identification and reduced development timelines.
Overall, AI in genomics is being established as a critical enabler of data-driven biology. Continued investment in data standardization, ethical governance, and interdisciplinary collaboration is expected to further strengthen its role in advancing genomic science globally.
Key Takeaways
- The global AI in genomics market is projected to reach approximately USD 35,267.3 million by 2033, expanding from USD 733.4 million in 2023.
- The market is anticipated to grow at a compound annual growth rate (CAGR) of 47.3% during the forecast period from 2024 to 2033.
- Based on components, the software segment dominated the market in 2023, accounting for 47.2% of the total market share.
- Among technology segments, machine learning held the leading position in 2023, capturing the largest share of the market.
- In terms of functionality, the genome sequencing segment emerged as the largest contributor, securing a 46.1% market share.
- By application, drug discovery and development represented the largest segment, contributing 34.4% of the overall market revenue.
- Pharmaceutical and biotechnology companies remained the primary end users of AI in genomics solutions in 2023.
- From a regional perspective, North America led the market, generating the highest revenue with a 31.7% market share in 2023.
AI in Genomics: Key Statistics
- Sharp Decline in Genome Sequencing Costs: The cost of sequencing a human genome has declined dramatically, falling from approximately USD 300 million for the first complete genome to nearly USD 100 today. This reduction has significantly improved accessibility and scalability for genomic research and clinical applications.
- Expansion of Genomic Diversity in the United States: The All of Us Research Program in the United States has accumulated genomic data from more than 250,000 individuals, with a strong emphasis on representation across diverse racial and ethnic populations. This diversity enhances the reliability and inclusiveness of genomic insights.
- Significant Contribution from the UK Biobank: The UK Biobank continues to serve as a major global repository of genomic and health data, providing researchers with extensive, high-quality datasets that support large-scale genetic and population health studies.
- Relative Scale of Genomic Data in AI: Although millions of human genomes have been sequenced, the total volume remains relatively small when compared with the billions of data points commonly used in AI domains such as image recognition and natural language processing. This highlights both the challenges and opportunities for AI model development in genomics.
- Rising Use of AI for Genomic Data Management: Global organizations are increasingly deploying AI technologies to manage and analyze genomic datasets, which can reach up to 100 terabytes per individual genome when raw and associated data are included. AI is essential for handling this scale and complexity efficiently.
Regional Analysis
In 2022, North America accounted for the largest share of the global AI in genomics market, capturing approximately 31.7% of total revenue. This leadership position was primarily supported by the strong presence of established market participants such as Danone, Abbott, Nestlé, Targeted Medical Pharma, Inc., and Mead Johnson & Company, LLC, among others.
Take advantage of our unbeatable offer - buy now!
The region benefits from the presence of some of the world’s largest and best-funded research institutions and biotechnology firms, which continue to make substantial investments in AI-driven genomic technologies. As a result, the development of advanced software platforms and analytical tools for genomic data interpretation has accelerated, thereby supporting sustained growth of the AI in genomics market across North America.
Emerging Trends in AI-Driven Genomics
- Enhanced Diagnostic Capabilities Through AI Integration: Artificial Intelligence is significantly improving the accuracy and speed of genomic diagnostics, particularly when combined with next-generation sequencing technologies. This integration enables more detailed genetic interpretation, supporting advancements in oncology, infectious disease research, and predictive healthcare.
- Growing Emphasis on Ethical and Transparent AI: There is a strong and increasing focus on the development of ethical, transparent, and interpretable AI systems in genomics. Efforts are being made to reduce algorithmic bias and improve explainability, which are critical for responsible adoption and equitable healthcare outcomes.
- Advancement of AI-Enabled Personalized Medicine: AI is accelerating the shift toward personalized medicine by enabling treatment strategies tailored to individual genetic profiles. This approach improves therapeutic precision, enhances treatment effectiveness, and supports better patient outcomes.
- Cross-Disciplinary Data Integration: AI is driving the integration of genomic data with other biological data types, such as proteomics and metabolomics. This multi-layered analysis provides deeper molecular insights into disease mechanisms and supports innovation in drug discovery and disease prediction.
- Strengthening Global Genomic Collaboration: AI technologies are facilitating international collaboration by enabling efficient analysis and sharing of genomic data across diverse populations. This global perspective supports improved understanding of disease patterns and the development of targeted public health interventions.
Key Use Cases of AI in Genomics
- Cancer Genomics: AI plays a critical role in identifying genetic mutations, predicting disease progression, and supporting the development of targeted cancer therapies. By analyzing large-scale genomic datasets, AI improves treatment selection and enhances the precision of oncology care.
- Infectious Disease Surveillance and Control: AI algorithms are used to analyze pathogen genomes to track mutations, monitor transmission patterns, and predict outbreak dynamics. These capabilities are essential for epidemic preparedness, response planning, and public health decision-making.
- Agricultural Biotechnology: In agriculture, AI supports genomic research aimed at enhancing crop resistance to diseases, pests, and environmental stress. These applications contribute to improved crop yields, sustainability, and global food security.
- Microbial Genomics: AI is widely applied in the analysis of microbial communities to understand their behavior, interactions, and environmental impact. This knowledge supports advancements in environmental management, industrial biotechnology, and microbial-based solutions.
- Genetic Disease Research: AI enables early detection of genetic abnormalities and rare disease markers by identifying complex genomic patterns. Early diagnosis supported by AI improves clinical decision-making and expands treatment opportunities, particularly for rare and inherited disorders.
Frequently Asked Questions on AI in Genomics
- How is AI improving genomic research efficiency?
AI improves genomic research efficiency by automating data processing, reducing manual analysis time, increasing accuracy in variant detection, and enabling researchers to interpret massive genomic datasets that were previously computationally impractical. - What types of AI technologies are used in genomics?
Common AI technologies used in genomics include machine learning, deep learning, natural language processing, and neural networks, which are applied to sequence alignment, variant calling, gene expression analysis, and predictive modeling. - What role does AI play in personalized medicine?
AI supports personalized medicine by analyzing individual genetic profiles to predict disease risks, optimize drug selection, and tailor treatment plans, thereby improving clinical outcomes and enabling more precise and patient-specific healthcare interventions. - What factors are driving market growth?
Market growth is driven by rising genomic data volumes, declining sequencing costs, increased adoption of precision medicine, expanding biotechnology research, and strong investments from pharmaceutical companies and government-backed genomics initiatives worldwide. - Which end-users are adopting AI in genomics solutions?
Primary end-users include pharmaceutical and biotechnology companies, academic research institutions, hospitals, diagnostic laboratories, and contract research organizations, all seeking improved efficiency, accuracy, and scalability in genomic analysis workflows. - How is AI impacting drug discovery within the genomics market?
AI accelerates drug discovery by identifying novel genetic targets, predicting drug-gene interactions, reducing development timelines, and lowering research costs, thereby enhancing productivity and success rates in genomics-driven pharmaceutical research. - What is the future outlook for the AI in genomics market?
The market outlook remains cautiously optimistic, supported by continuous technological advancements, expanding clinical applications, regulatory progress, and increasing integration of AI-driven genomics into routine healthcare and life sciences research ecosystems.
Conclusion
AI in genomics is being firmly established as a transformative force in modern life sciences, enabling scalable, accurate, and data-driven interpretation of complex genetic information. Rapid declines in sequencing costs, expanding genomic datasets, and advances in machine learning are collectively strengthening adoption across healthcare, biotechnology, and pharmaceutical research.
Strong market growth is being supported by precision medicine, drug discovery, and diagnostics applications, particularly in North America. While challenges related to data standardization, ethics, and model transparency remain, continued investment and cross-disciplinary collaboration are expected to sustain long-term innovation. Overall, AI-driven genomics represents a critical pillar for the future of personalized and predictive biology.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
